The GLP-1 RAs Wegovy, Ozempic, Mounjaro, and Zepbound have taken up more real estate on the US map in some areas than others. Click to find out more.
When it comes overweight, obesity, and prescription drugs for weight loss, these results from the National Poll on Healthy Aging suggest older US adults need guidance.
Use of nonprescribed weight loss products was higher among girls than boys globally and led by diet pills, followed by laxatives and diuretics, a meta-analysis found.
Your daily dose of the clinical news you may have missed.
While the FDA's preliminary evaluation has not surfaced evidence of a link, the agency says it "cannot definitively rule out that a small risk may exist," and so will continue research.
Individuals with "lean NAFLD" may be at similar risk of NASH, cirrhosis, nonliver cancer, and death as as those with NAFLD and overweight or obesity, authors say.
In an open letter to the public, Lilly decries use of tirzepatide products Mounjaro and Zepbound for nonmedical purposes and warns of counterfeit formulations.
Your daily dose of the clinical news you may have missed.
The American Board of Obesity Medicine says annual first-time certificates now exceed those for cardiology, pulmonology, and medical oncology.
Study participants randomized to placebo for 1 year after 36 weeks on tirzepatide had mean weight regain of 14% vs augmented loss among those who continued on the medication.